In the context of where this is going, Q2 means nothing. This company has struggled for years to get recognition not just of its product, but of the technology as a viable medical option. It was far ahead of its time and now its time has arrived and it is well positioned to become a leader as an alternative to opioid options. I think the longs here have that kind of perspective. Those on the sidelines and critical of every sneeze have their own agenda. All IMHO. GLTA longs.
News 
Market Data 
Discover 
